Overview At the Multi‑Omics Summit 2026 , Union Minister of State (Independent Charge) for Science & Technology, Dr Jitendra Singh declared that India is moving from a phase of seeking advanced treatment abroad to becoming a global destination for precision medicine, biomanufacturing and medical innovation. Key Developments Launch of the comprehensive BioE3 policy . Allocation of ₹10,000 crore under the Biopharma Shakti scheme . Growth of biotech ecosystem to **over 11,000 startups**, up from a few dozen a decade ago. Progress in large‑scale genomics: completion of ~10,000 genome sequences under the Genome India Project , with the upcoming Phenome India initiative. Integration of precision medicine with AI, traditional systems like Ayurveda, and modern biotech. Opening of the nuclear sector to private participation, fostering innovation in nuclear medicine. Important Facts The Ministry of AYUSH and expanded biotechnology platforms have enabled hybrid healthcare models. Recent breakthroughs include gene‑based therapies for sickle‑cell disease and hemophilia, and nuclear‑medicine treatments for acute lymphoblastic leukaemia at Tata Memorial Centre. India’s genetically diverse population provides a unique advantage for multi‑omics research, allowing the identification of disease patterns across varied ethnic groups. UPSC Relevance Understanding the bio‑economy and its policy framework aligns with GS‑3 topics on science‑technology and economic growth. Knowledge of the Biopharma Shakti helps answer questions on Make‑in‑India and health‑sector self‑reliance. Insights into the integration of traditional systems (AYUSH) with modern biotech are pertinent for GS‑2 (Polity) and GS‑4 (Ethics) discussions on cultural heritage and innovation. Multi‑omics and precision medicine illustrate the role of AI and data‑driven health governance, a recurring theme in GS‑3 and GS‑4. Way Forward To sustain momentum, the government must: Strengthen public‑private partnerships for research and manufacturing. Ensure robust data‑privacy and ethical frameworks for genomic databases. Scale up skill development programmes to create a skilled biotech workforce. Promote export‑oriented biopharma clusters to capture global market share. With continued policy support and a vibrant research ecosystem, India can lead the next wave of global healthcare innovation.